stockrowCerenome, Inc.
CNSY Healthcare Biotechnology
Cerenome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.2 million, down 10.5% from fiscal 2024.
- Revenue
- −70.4%
- EPS
- −311.3%
- Free cash flow
- −31.5%
Quarter to June 2026, against a year earlier
Follow CNSY
Alert me
Cerenome, Inc. (CNSY) EV/Sales
As of 6 November 2026, Cerenome, Inc. (CNSY) trades at a EV/Sales of 1.5×. Over the past ten years it has ranged from −23.3× (March 2023) to 62,881,478× (March 2015); the current reading is higher than 39% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.8× | 258.51% |
| FY2024 | 1.9× | 86.77% |
| FY2023 | 1.0× | — |
| FY2022 | −23.1× | — |
| FY2020 | −0.1× | — |
| FY2019 | −0.8× | — |
| FY2018 | 5.6× | 27.72% |
| FY2017 | 4.4× | (99.99%) |
| FY2016 | 74,275× | (92.84%) |
| FY2015 | 1,036,719× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 7.7× | 142.52% |
| Mar 2026 | 3.2× | (53.75%) |
| Dec 2025 | 6.8× | (43.75%) |
| Sep 2025 | 12.2× | 279.26% |
| 34 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CANF Can-Fite Biopharma Ltd compare | −8.7× |
| SNTI Senti Biosciences, Inc. compare | −1.1× |
| RVPH Reviva Pharmaceuticals Holdings, Inc. compare | n/m |
| ACXP Acurx Pharmaceuticals, Inc. compare | n/m |
| PULM Pulmatrix, Inc. compare | 0.8× |
| CNSY Cerenome, Inc. | 1.5× |
| IMNN Imunon, Inc. compare | 6.2× |
| PCSA Heatwurx Inc. compare | 49.5× |
| CDIO Cardio Diagnostics Holdings, Inc. compare | 61.5× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)